Oncology radiopharmaceuticals are types of regulated, radioactive tracers used to detect and treat various types of cancers. They help in early detection of tumors through techniques like Positron Emission Tomography (PET) scans and Single Photon Emission Computed Tomography (SPECT) scans. Oncology radiopharmaceuticals provide non-invasive diagnostic and therapeutic procedures that aid accurate diagnosis and treatment of cancer.
The global Oncology Radiopharmaceuticals Market is estimated to be valued at US$ 7351 Mn in 2023 and is expected to exhibit a CAGR of 3.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Opportunity:
The opportunity in cancer diagnostics is expected to drive the growth of the oncology radiopharmaceuticals market. Radiopharmaceuticals play a key role in cancer diagnostics by enabling early and accurate detection of tumors through imaging procedures like PET and SPECT scans. With rising cancer incidence globally, the demand for advanced non-invasive diagnostic procedures like PET/CT scans is increasing. It is estimated that over 20 million new cancer cases are detected annually worldwide. Thus, the growing burden of cancer presents a lucrative opportunity for radiopharmaceutical manufacturers to introduce innovative diagnostic radiotracers and gain market share in the oncology diagnostics segment. This will significantly contribute to the expansion of the oncology radiopharmaceuticals market during the forecast period.
Porter's Analysis
Threat of new entrants: The threat is moderate as the market requires high capital investment and stringent regulations. However, new biotechnology firms can enter the market with their innovative drugs and technologies.
Bargaining power of buyers: The bargaining power of buyers is high due to the presence of many regional and local players. Buyers can easily switch between suppliers based on price and quality.
Bargaining power of suppliers: The bargaining power of suppliers is moderate as key raw materials suppliers are few. However, suppliers have less bargaining power due to the availability of substitutes.
Threat of new substitutes: The threat of new substitutes is moderate as research leads to innovative radiopharmaceutical products. However, high switching costs limit the threat.
Competitive rivalry: The competition is high among existing players like Ecolab, BASF, and Solvay to gain higher market share.
SWOT Analysis
Strengths: Growing usage in diagnosing and treating cancer patients. Innovative drug development and imaging technologies.
Weaknesses: High manufacturing costs. Stringent regulatory approvals. Short half-life limits applications.
Opportunities: Untapped potential in developing countries. Growing cases of cancer worldwide. Collaborations for advanced radiotracers.
Threats: Adoption of alternative cancer treatment methods. Reimbursement issues. Supply chain disruptions.
Key Takeaways
The Global Oncology Radiopharmaceuticals Market Growth is expected to witness high over the forecast period due to the growing cancer prevalence. The global oncology radiopharmaceuticals market is estimated to be valued at US$ 7351 Mn in 2023 and is expected to exhibit a CAGR of 3.2% over the forecast period 2023 to 2030.
The North American region currently dominates the market due to supportive regulations and significant healthcare expenditure. Regional analysis indicates that Asia Pacific will be the fastest growing market owing to improving healthcare infrastructure and increasing healthcare budget in major countries like China and India.
Key players operating in the oncology radiopharmaceuticals market are Ecolab Inc., BASF SE, Solvay S.A., FQE Chemicals, Innospec Inc., Stepan Company, Dow Inc., Kemira Oyj, GE Water and Process Technologies, and Aries Chemical Inc. These key players are focusing on new product launches, collaborations and geographic expansion to strengthen their market position. For instance, in 2023, Ecolab partners with BASF for global supply of raw materials to meet increasing customer demand.
Explore more information on this topic, Please visit-
Comments
0 comment